Principal Financial Group
MRNA icon

Principal Financial Group’s Moderna MRNA Stock Holding History

Principal Financial Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27M Sell
385,424
-2,294
-0.6% -$119K 0.01% 815
2026
Q1 		$19.7M Buy
387,718
+3,790
+1% +$177K 0.01% 938
2025
Q4 		$11.3M Buy
383,928
+10,874
+3% +$295K 0.01% 1237
2025
Q3 		$9.64M Buy
373,054
+1,442
+0.4% +$40.2K ﹤0.01% 1310
2025
Q2 		$10.3M Sell
371,612
-9
-0% -$237 0.01% 1253
2025
Q1 		$10.5M Sell
371,621
-1,863
-0.5% -$66.1K 0.01% 1227
2024
Q4 		$15.5M Sell
373,484
-5,967
-2% -$285K 0.01% 1024
2024
Q3 		$25.4M Buy
379,451
+15,218
+4% +$1.4M 0.01% 722
2024
Q2 		$43.3M Buy
364,233
+328
+0.1% +$41.5K 0.03% 509
2024
Q1 		$38.8M Buy
363,905
+2,948
+0.8% +$297K 0.02% 569
2023
Q4 		$35.9M Sell
360,957
-1,949
-0.5% -$164K 0.02% 561
2023
Q3 		$37.5M Buy
362,906
+742
+0.2% +$82.8K 0.03% 509
2023
Q2 		$44M Sell
362,164
-17,351
-5% -$2.31M 0.03% 467
2023
Q1 		$58.3M Buy
379,515
+5,614
+2% +$926K 0.04% 383
2022
Q4 		$67.2M Sell
373,901
-16,962
-4% -$2.77M 0.05% 312
2022
Q3 		$46.2M Sell
390,863
-18,924
-5% -$2.87M 0.04% 404
2022
Q2 		$58.5M Sell
409,787
-18,835
-4% -$2.69M 0.04% 350
2022
Q1 		$73.8M Sell
428,622
-468
-0.1% -$78.8K 0.05% 327
2021
Q4 		$109M Sell
429,090
-8,293
-2% -$2.42M 0.07% 249
2021
Q3 		$168M Buy
437,383
+402,212
+1,144% +$148M 0.11% 191
2021
Q2 		$8.27M Sell
35,171
-60,326
-63% -$10.8M 0.01% 1511
2021
Q1 		$12.5M Buy
95,497
+4,648
+5% +$674K 0.01% 1273
2020
Q4 		$9.49M Sell
90,849
-12,991
-13% -$1.31M 0.01% 1263
2020
Q3 		$7.35M Sell
103,840
-5,828
-5% -$406K 0.01% 1253
2020
Q2 		$7.04M Buy
109,668
+34,291
+45% +$1.88M 0.01% 1263
2020
Q1 		$2.26M Buy
75,377
+5,009
+7% +$115K ﹤0.01% 1561
2019
Q4 		$1.38M Buy
70,368
+19,482
+38% +$346K ﹤0.01% 1782
2019
Q3 		$810K Sell
50,886
-24
-0% -$355 ﹤0.01% 1857
2019
Q2 		$745K Buy
+50,910
New +$1.09M ﹤0.01% 1888

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Principal Financial Group's MRNA Position: Q2 2026 in Review

Principal Financial Group reduced its Moderna (MRNA) stake by 0.59% in Q2 2026, selling an estimated $119K and leaving 385,424 shares worth $27M. The position accounts for 0.01% of the portfolio, ranked #815.

Principal Financial Group first reported a position in MRNA in Q2 2019 and has held it in 29 quarters since. The position peaked at $168M in Q3 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Principal Financial Group held 385,424 shares of Moderna worth $27M as of Q2 2026.
  • Principal Financial Group sold 2,294 Moderna shares in Q2 2026, an estimated $119K.
  • Moderna made up 0.01% of Principal Financial Group's portfolio in Q2 2026, its #815 holding.
  • Principal Financial Group first reported a position in Moderna in Q2 2019 and has held it in 29 quarters since.
  • Principal Financial Group's Moderna position peaked at $168M in Q3 2021.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Principal Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.